Illumina offers a portfolio across the reproductive health continuum. Focusing on preconception and fertility, our innovative preimplantation genetic screening (PGS) technology aims to help increase in vitro fertilization (IVF) success rates, and our preimplantation genetic diagnosis (PGD) technology is designed to be used in conjunction with IVF to reduce the transmission of known genetic conditions.
As a global leader in DNA sequencing and microarray-based solutions, Illumina is dedicated to improving human health by unlocking the power of the genome. Serving customers in the research, clinical, and applied markets, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, agriculture, microbiology, forensic science, and beyond. By empowering large-scale analysis of genetic variation and function, Illumina is enabling studies that were not imaginable just a few years ago, moving us closer to the realization of precision medicine.